GtoPdb Ligand ID: 7874

Synonyms: BAY 10-00394 | BAY 1000394 | KB-145902
Compound class: Synthetic organic
Comment: Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, with selectively for CDK1/cyclin B, CDK2/cyclin E, CDK4/cyclin D1, and CDK9/cyclin T1, which play key roles in the regulation of cell cycle progression and cellular proliferation [1-2].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 116.57
Molecular weight 430.13
XLogP 3.85
No. Lipinski's rules broken 0
Canonical SMILES CC(C(Oc1nc(ncc1C(F)(F)F)Nc1ccc(cc1)S(=O)(=N)C1CC1)C)O
Isomeric SMILES C[C@H]([C@H](Oc1nc(ncc1C(F)(F)F)Nc1ccc(cc1)S(=O)(=N)C1CC1)C)O
InChI InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29?/m1/s1
No information available.
Summary of Clinical Use
Roniciclib was assessed in Phase 2 clinical trials principally for lung cancers, however all trials were terminated or withdrawn, and further development was discontinued by the drug's sponsor, Bayer.
Mechanism Of Action and Pharmacodynamic Effects
Inhibition of the CDK kinases lead to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells